Scleroderma renal crisis: pathogenesis issues, disease pattern and modern approaches to the treatment
Journal Title: Нирки - Year 2018, Vol 7, Issue 4
Abstract
Scleroderma renal crisis (SRC) is a major complication in patients with systemic sclerosis. SRC occurs in about 5–25 % of all patients with scleroderma. It is characterized by malignant hypertension and olig-/anuric acute renal failure. Around 10 % of SRC cases may present with normal blood pressure, termed normotensive renal crisis. The etiopathogenesis is presumed to be a series of insults to the kidneys resulting in endothelial injury, intimal proliferation, and narrowing of renal arterioles leading to decreased blood flow, hyperplasia of the juxtaglomerular apparatus, hyperreninemia, and accelerated hypertension. SRC is often triggered by nephrotoxic drugs and/or intravascular volume depletion. SRC occurs particularly in the first years of disease and in its diffuse form. The occurrence of SRC is more common in patients treated with glucocorticoids, the risk increases with increasing dose. Left ventricular insufficiency and hypertensive encephalopathy are typical clinical features. Thrombotic microangiopathy is detected in 43 % of the cases. Anti-RNA-polymerase III antibodies are present in one third of patients who develop SRC. Renal biopsy is not necessary if SRC presents with classical features. However, it can help to establish prognosis and approaches to the treatment in atypical forms. The prognosis of SRC has dramatically improved with the introduction of angiotensin-converting enzyme inhibitors. However, 5-year survival in patients with systemic sclerosis who develop the full picture of SRC remains low (65 %). The treatment of SRC is based on aggressive control of blood pressure with angiotensin-converting enzyme inhibitors, if needed, in combination with other types of antihypertensive drugs. Dialysis is frequently indicated, but can be stopped in approximately half of patients, mainly in those with good control of blood pressure. Patients who need dialysis for more than 2 years qualify for renal transplantation. SRC still remains an important cause of morbidity and mortality in scleroderma. Prompt diagnosis and treatment may help prevent adverse outcomes and improve survival.
Authors and Affiliations
I. Yu. Golovach, Ye. D. Yehudina
Keywords
Related Articles
- EP ID EP421443
- DOI 10.22141/2307-1257.7.4.2018.148521
- Views 85
- Downloads 0
Pathogenesis and potential therapy of autosomal dominant polycystic kidney disease
Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary disease characterized by progressive growth of the cyst and an increase in the total volume of the kidneys which leads to kidney failure. The main caus...
Clinical Nephrology in Mutual Integration of Medical Professions
.
Statins in Nephrology: What does the Guidelines Say?
.
Thyroid dysfunction and kidney diseases
Thyroid hormones provide normal functioning of the kidneys, which in turn are not only an organ for the metabolism and excretion of thyroid hormones but also serve as targets for the action of certain thyroid hormones. H...
The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology
The vast majority of acute heart failure episodes are characterized by increasing symptoms and signs of congestion with volume overload. The goal of therapy in those patients is the relief of congestion through achieving...